Integrated urine proteomics and renal single-cell genomics identify an IFN-γ response gradient in lupus nephritis.
Autoimmunity
Lupus
Nephrology
Proteomics
Th1 response
Journal
JCI insight
ISSN: 2379-3708
Titre abrégé: JCI Insight
Pays: United States
ID NLM: 101676073
Informations de publication
Date de publication:
18 06 2020
18 06 2020
Historique:
received:
20
03
2020
accepted:
06
05
2020
pubmed:
13
5
2020
medline:
9
6
2021
entrez:
13
5
2020
Statut:
epublish
Résumé
Lupus nephritis, one of the most serious manifestations of systemic lupus erythematosus (SLE), has a heterogeneous clinical and pathological presentation. For example, proliferative nephritis identifies a more aggressive disease class that requires immunosuppression. However, the current classification system relies on the static appearance of histopathological morphology, which does not capture differences in the inflammatory response. Therefore, a biomarker grounded in the disease biology is needed in order to understand the molecular heterogeneity of lupus nephritis and identify immunologic mechanism and pathways. Here, we analyzed the patterns of 1000 urine protein biomarkers in 30 patients with active lupus nephritis. We found that patients stratify over a chemokine gradient inducible by IFN-γ. Higher values identified patients with proliferative lupus nephritis. After integrating the urine proteomics with the single-cell transcriptomics of kidney biopsies, we observed that the urinary chemokines defining the gradient were predominantly produced by infiltrating CD8+ T cells, along with natural killer and myeloid cells. The urine chemokine gradient significantly correlated with the number of kidney-infiltrating CD8+ cells. These findings suggest that urine proteomics can capture the complex biology of the kidney in lupus nephritis. Patient-specific pathways could be noninvasively tracked in the urine in real time, enabling diagnosis and personalized treatment.
Identifiants
pubmed: 32396533
pii: 138345
doi: 10.1172/jci.insight.138345
pmc: PMC7406291
doi:
pii:
Substances chimiques
Biomarkers
0
Chemokines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAMS NIH HHS
ID : UH2 AR067694
Pays : United States
Organisme : NIAMS NIH HHS
ID : UH2 AR067689
Pays : United States
Organisme : NIAMS NIH HHS
ID : UM2 AR067678
Pays : United States
Organisme : NIAMS NIH HHS
ID : UH2 AR067691
Pays : United States
Organisme : NIAMS NIH HHS
ID : UH2 AR067685
Pays : United States
Organisme : NIAMS NIH HHS
ID : UH2 AR067681
Pays : United States
Organisme : NIAMS NIH HHS
ID : UH2 AR067677
Pays : United States
Organisme : NIAMS NIH HHS
ID : UH2 AR067688
Pays : United States
Organisme : NIAMS NIH HHS
ID : R01 AR069572
Pays : United States
Organisme : NIAMS NIH HHS
ID : UH2 AR067679
Pays : United States
Organisme : NIAMS NIH HHS
ID : UH2 AR067690
Pays : United States
Organisme : NIAMS NIH HHS
ID : UH2 AR067676
Pays : United States
Références
Semin Nephrol. 2015 Sep;35(5):455-64
pubmed: 26573548
Lupus Sci Med. 2014 Apr 01;1(1):e000004
pubmed: 25396056
Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2610-5
pubmed: 12604793
Eur J Immunol. 2017 Jan;47(1):180-192
pubmed: 27753073
Lancet. 2018 Jul 21;392(10143):222-231
pubmed: 30043749
Kidney Int. 2018 Oct;94(4):788-794
pubmed: 30045812
Genome Biol. 2016 Apr 28;17:77
pubmed: 27121950
J Exp Med. 2003 Mar 17;197(6):711-23
pubmed: 12642603
J Autoimmun. 2019 Jan;96:1-13
pubmed: 30448290
Ann Rheum Dis. 2016 Nov;75(11):2014-2021
pubmed: 27088255
Sci Immunol. 2019 Dec 6;4(42):
pubmed: 31811055
Lancet. 2018 Oct 13;392(10155):1330-1339
pubmed: 30249507
Arthritis Rheum. 2012 Aug;64(8):2687-97
pubmed: 22328173
Rheumatology (Oxford). 2002 May;41(5):518-24
pubmed: 12011374
J Allergy Clin Immunol. 2015 Mar;135(3):626-35
pubmed: 25528359
Discov Med. 2013 Sep;16(87):123-31
pubmed: 23998448
N Engl J Med. 2005 Nov 24;353(21):2219-28
pubmed: 16306519
Arthritis Rheumatol. 2014 Feb;66(2):369-78
pubmed: 24504809
Arthritis Rheum. 1998 Jul;41(7):1173-80
pubmed: 9663472
Arthritis Rheum. 2001 Sep;44(9):2097-106
pubmed: 11592372
Nucleic Acids Res. 2013 Jan;41(Database issue):D1040-6
pubmed: 23203888
Nat Genet. 2000 May;25(1):25-9
pubmed: 10802651
Arthritis Rheumatol. 2017 Oct;69(10):1996-2005
pubmed: 28891237
Arthritis Rheum. 2013 Aug;65(8):2154-60
pubmed: 23754671
Arthritis Rheumatol. 2017 Oct;69(10):2006-2017
pubmed: 28891252
J Immunol. 2011 Jul 1;187(1):538-52
pubmed: 21613614
J Am Soc Nephrol. 2004 Feb;15(2):241-50
pubmed: 14747370
J Leukoc Biol. 2018 Sep;104(3):499-514
pubmed: 29999544
Nat Immunol. 2019 Jul;20(7):915-927
pubmed: 31110316
Arthritis Rheumatol. 2014 Feb;66(2):357-68
pubmed: 24504808
J Exp Med. 2016 May 2;213(5):733-50
pubmed: 27069113
Rheumatology (Oxford). 2003 Aug;42(8):935-8
pubmed: 12730502
J Rheumatol. 2012 Jun;39(6):1231-7
pubmed: 22505707
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
Arthritis Care Res (Hoboken). 2012 Jun;64(6):797-808
pubmed: 22556106
JCI Insight. 2017 May 4;2(9):
pubmed: 28469080
Lupus. 2017 Jul;26(8):865-870
pubmed: 27927880
J Exp Med. 2016 May 2;213(5):715-32
pubmed: 27069112
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):17609-14
pubmed: 23045702
J Immunol. 1998 Jul 1;161(1):494-503
pubmed: 9647261
Commun Biol. 2019 Apr 23;2:140
pubmed: 31044165
Arthritis Rheum. 2004 Dec;50(12):3958-67
pubmed: 15593221
Nucleic Acids Res. 2019 Jan 8;47(D1):D330-D338
pubmed: 30395331
Nat Immunol. 2019 Jul;20(7):902-914
pubmed: 31209404
Clin Immunol. 2017 Dec;185:10-20
pubmed: 27498110
J Immunol. 1998 Apr 15;160(8):3713-8
pubmed: 9558072
FEBS Lett. 1999 Jun 18;453(1-2):187-90
pubmed: 10403400
Arthritis Rheumatol. 2014 Sep;66(9):2494-502
pubmed: 24891315